Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Colorectal Cancer Reports
Erschienen in: Current Colorectal Cancer Reports 1/2016

01.02.2016 | Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)

The Role of Neoadjuvant Chemotherapy in Patients With Resectable Colorectal Metastases: Where Are We Now?

verfasst von: Hans F. Schoellhammer, Gagandeep Singh, Yuman Fong

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Approximately 25 % of patients with colorectal cancer (CRC) have colorectal liver metastases (CRLMs) at the time of diagnosis, and up to 60 % of CRC patients will develop CRLM during the course of their disease. Complete surgical resection of CRLM affords patients the possibility of long-term cure. With modern chemotherapy, shrinkage in the size of unresectable CRLM may allow patients to undergo surgery. However, the role of chemotherapy given prior to surgery for patients with already-resectable CRLM at the time of presentation is unclear. Currently, the use of neoadjuvant chemotherapy (NAC) is an area of controversy in which few randomized prospective data exist to guide its use. In this review, we examine the literature and data for neoadjuvant chemotherapy for resectable CRLM. We review advantages and disadvantages of NAC and discuss rational indications for NAC use in resectable CRLM.
Literatur
1.
DeSantis CE et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMed
2.
Donadon M et al. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res. 2007;1(1):20–7.PubMedPubMedCentral
3.
Abdalla EK et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.CrossRefPubMed
4.
Baden H, Andersen B. Survival of patients with untreated liver metastases from colorectal cancer. Scand J Gastroenterol. 1975;10(2):221–3.PubMed
5.
Bengtsson G et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141(5):586–9.CrossRefPubMed
6.
Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78(3–4):237–48.CrossRefPubMed
7.
Abdalla EK et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25. discussion 825–7.CrossRefPubMedPubMedCentral
8.
Charnsangavej C et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1261–8.CrossRefPubMed
9.
10.
Adam R et al. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am. 2007;16(3):525–36. viii.CrossRefPubMed
11.
Ekberg H et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73(9):727–31.CrossRefPubMed
12.
Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13(1):51–64.CrossRefPubMed
13.
Evrard S et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One. 2014;9(12):e114404.CrossRefPubMedPubMedCentral
14.
Ferrero A et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg. 2007;31(8):1643–51.CrossRefPubMed
15.
Fong Y et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 318–21.CrossRefPubMedPubMedCentral
16.
Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12(1):165–92. xi.CrossRefPubMed
17.
Van Cutsem E et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.CrossRefPubMed
18.
Jones RP et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99(4):477–86.CrossRefPubMed
19.
Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005;23(22):4853–5.CrossRefPubMed
20.
Allen PJ et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7(1):109–15. discussion 116–7.CrossRefPubMed
21.
Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12(7):825–39.CrossRefPubMed
22.
Adam R et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57. discussion 657–8.PubMedPubMedCentral
23.
Adam R et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26(10):1635–41.CrossRefPubMed
24.
Tanaka K et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90(8):963–9.CrossRefPubMed
25.
Peppercorn PD et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77(11):2008–11.CrossRefPubMedPubMedCentral
26.
Narita M et al. What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy? Ann Surg Oncol. 2012;19(8):2526–38.CrossRefPubMed
27.
Lehmann K et al. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg. 2012;255(2):237–47.CrossRefPubMed
28.
Rubbia-Brandt L et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.CrossRefPubMed
29.
Kooby DA et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7(8):1034–44.CrossRefPubMed
30.
Zorzi D et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274–86.CrossRefPubMed
31.
Vauthey JN et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.CrossRefPubMed
32.
Benoist S et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939–45.CrossRefPubMed
33.
van Vledder MG et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691–700.CrossRefPubMed
34.
Elias D et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86(1):4–9.CrossRefPubMed
35.
Auer RC et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010;116(6):1502–9.CrossRefPubMed
36.
Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.CrossRefPubMedPubMedCentral
37.••
Nordlinger B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. The long-term follow-up from the EORTC Intergroup trail 40983 did not demonstrate any long-term difference in the overall survival between the perioperative chemotherapy group and the surgery group.CrossRefPubMed
38.
Adam R et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–61. discussion 1061–4.CrossRefPubMedPubMedCentral
39.
Gallagher DJ et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol. 2009;16(7):1844–51.CrossRefPubMed
40.
Reddy SK et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16(7):1809–19.CrossRefPubMed
41.
Scoggins CR et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009;16(1):35–41.CrossRefPubMed
42.
Boxberger F et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Med Sci Monit. 2010;16(2):CR49–55.PubMed
43.
Oh SY et al. Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases. J Surg Res. 2013;182(2):257–63.CrossRefPubMed
44.
Araujo R et al. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol. 2013;20(13):4312–21.CrossRefPubMed
45.
Nasti G et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108(8):1566–70.CrossRefPubMedPubMedCentral
46.
47.••
Bonney GK et al. Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; an international multi-center data analysis using LiverMetSurvey. J Surg Oncol. 2015;111(6):716–24. Results of a large international database of 1301 patients demonstrate no increase in overall survival at 1 and 3 years after resection with the use of perioperative chemotherapy versus surgery first for resectable CRLM.CrossRefPubMed
48.
Adam R et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252(5):774–87.CrossRefPubMed
49.
Nigri G et al. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies. Surgeon. 2015;13(2):83–90.CrossRefPubMed
50.•
Jones RP et al. Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol. 2013;39(8):807–11. Recommendations for rational stratification of patients with CRLM into three groups. Patients with resectable CRLM at presentation should undergo surgical resection followed by adjuvant chemotherapy if appropriate. Neoadjuvant chemotherapy for resectable CRLM reserved for masses very borderline resectable or with high risk for recurrence based on disease biology.CrossRefPubMed
51.
Jones RP et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg. 2012;99(9):1263–9.CrossRefPubMed
52.•
Karagkounis G et al. The role of neoadjuvant therapy in characterizing indeterminate lung lesions in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2015;22(7):2201–8. Rational use of neoadjuvant chemotherapy for resectable CRLM in cases where it is unsure if the patient has extrahepatic metastatic disease. The authors found in their single-institution series that 23 % of indeterminate pulmonary nodules were pulmonary metastases.CrossRefPubMed
53.
54.
Ayez N et al. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer. 2015;15:180.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Role of Neoadjuvant Chemotherapy in Patients With Resectable Colorectal Metastases: Where Are We Now?
verfasst von
Hans F. Schoellhammer
Gagandeep Singh
Yuman Fong
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 1/2016
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-016-0303-z

Weitere Artikel der Ausgabe 1/2016

Current Colorectal Cancer Reports 1/2016 Zur Ausgabe

Prevention and Early Detection (R Benamouzig, Section Editor)

How Can We Improve Adenoma Detection Rate?

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?

Prevention and Early Detection (R Benamouzig, Section Editor)

Is Curcumin a Chemopreventive Agent for Colorectal Cancer?

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Optimizing Colorectal Cancer Care in Older Patients

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment?

Translational Colorectal Oncology (Y Jiang, Section Editor)

The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise